Appendix 4E & FY26 Annual Report
Filed with ASX · · 59 pages · English
Summary by 6ix AI
The report highlights a revenue increase from operations, although the company reported a loss before tax due to various non-cash items and ongoing investments. The filing also notes that no dividends were declared during the current or prior financial years, and the financial statements have been audited with an unmodified opinion issued.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
PharmX Technologies Limited on 6ix
Earlier from PharmX Technologies
- H1 FY26 Investor Presentation
- Half Yearly Reports & Accounts
- H1 FY26 Results Announcement
- Pharmx and Sigma enter multi-year strategic alliance
- Investor Presentation
Later from PharmX Technologies
All PharmX Technologies news releasesFollow PharmX Technologies into a list and get an email when it puts out news.
Follow PharmX Technologies